Company intelligence / Profile preview
Incanthera
Manchester, England, United Kingdomincanthera.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
Incanthera has developed a revolutionary skincare range called Skin + CELL using its proprietary biotech delivery platform. The company signed a major commercial deal with Marionnaud (A.S. Watson Group) in December 2023 to launch this product line. Commercial revenues are expected from September 2024 onward with projected annual revenues exceeding £10 million in 2024. The company’s technology aims to deliver actives into skin cells to optimize repair and protection functions.
- Therapeutic areas
- Dermatology
- Modalities
- Small molecules (via unique formulation and delivery technologies for dermatology and oncology)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Marionnaud / A.S. Watson Group – exclusive commercial partnership for Skin + CELL range rollout across Europe starting late 2024
Beyond the preview
Go deeper on Incanthera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Incanthera.